Grey

Grey Wolf Therapeutics is a clinical-stage biotechnology company pioneering a novel approach to immuno-oncology known as antigen neo-generation. The company's strategy involves using small molecule inhibitors to target the endoplasmic reticulum aminopeptidases ERAP1 and ERAP2, which are key enzymes in the antigen processing pathway. By modulating these targets, Grey Wolf aims to change the landscape of neoantigens presented on tumor cells, making previously "cold" tumors visible to the T cells of the immune system. Their lead program, GRW4352, is an ERAP1 inhibitor currently in Phase 1/2 clinical development for advanced solid tumors. The company is headquartered in Oxford, UK, and is backed by leading life science investors.